Numis Securities Raises Puretech Health (PRTC) Price Target to GBX 233

Puretech Health (LON:PRTC) had its target price increased by research analysts at Numis Securities from GBX 207 ($2.77) to GBX 233 ($3.12) in a report released on Thursday. The firm currently has a “buy” rating on the stock. Numis Securities’ price target indicates a potential upside of 84.55% from the company’s current price.

A number of other research firms have also issued reports on PRTC. Liberum Capital reiterated a “buy” rating and issued a GBX 248 ($3.32) target price on shares of Puretech Health in a research note on Monday, September 25th. Peel Hunt reiterated a “buy” rating and issued a GBX 278 ($3.72) target price on shares of Puretech Health in a research note on Monday, November 6th. N+1 Singer reiterated a “buy” rating on shares of Puretech Health in a research note on Wednesday, August 30th. Finally, Jefferies Group reiterated a “buy” rating on shares of Puretech Health in a research note on Friday, November 17th. Five investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of GBX 248 ($3.32).

Puretech Health (LON PRTC) traded up GBX 1.88 ($0.03) during mid-day trading on Thursday, hitting GBX 126.25 ($1.69). The stock had a trading volume of 243,476 shares, compared to its average volume of 41,921. Puretech Health has a fifty-two week low of GBX 110 ($1.47) and a fifty-two week high of GBX 139 ($1.86).

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/numis-securities-raises-puretech-health-prtc-price-target-to-gbx-233.html.

About Puretech Health

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.

Analyst Recommendations for Puretech Health (LON:PRTC)

Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply